在对室内尘螨过敏的哮喘患儿中，3年皮下SQ-标准化特异性免疫治疗的疗效分析
2014/04/15
摘要
本研究旨在评估3年皮下SQ-标准化特异性免疫治疗(SCIT)对室内尘螨(HDM)过敏的哮喘儿童的作用。90例对HDMs过敏的哮喘儿童(伴或不伴过敏性鼻炎)被随机分成治疗组和对照组。治疗组接受SCIT联合标准的糖皮质激素治疗，对照组单用标准的糖皮质激素治疗，治疗疗程均为3年。在治疗前和治疗后1年、2年和3年，评估平均每日糖皮质激素(ICSs) 吸入量，每四周记录的哮喘症状评分，呼吸流量峰值（PEF），皮肤点刺试验结果和血清免疫球蛋白E（IgE）水平。与对照组相比，治疗2年和3年后治疗组的ICS的中值剂量减少。治疗3年后，治疗组的ICS停药比率比对照组更高。治疗2年和3年后治疗组与对照组相比，日间和夜间哮喘症状评分显著减少， PEF值增加，血清IgE水平降低（P＜0.05）。总而言之，3年SCIT联合ICS对儿童过敏性哮喘是一种有效的免疫治疗方法，可减少ICS的必须剂量。
（苏楠 审校）
Exp Ther Med. 2014 Mar;7(3):630-634. Epub 2014 Jan 2.
Efficacy analysis of three-year subcutaneous SQ-standardized specific immunotherapy in house dust mite-allergic children with asthma.
Hui Y, Li L, Qian J, Guo Y, Zhang X, Zhang X.
Abstract
The present study aimed to evaluate the efficacy of three-year subcutaneous SQ-standardized specific immunotherapy (SCIT) in house dust mite (HDM)-allergic children with asthma. Ninety children with allergic asthma to HDMs, with or without allergic rhinitis, were randomly divided into two groups, the treatment group and the control group. The treatment group received SCIT combined with standardized glucocorticoid management and the control group received standardized glucocorticoid management alone for a period of three years. The mean daily dose of inhaled corticosteroids (ICSs), a four-week diary recording the symptom scores of asthma, peak expiratory flow (PEF) measurements, skin prick test results and serum immunoglobulin E (IgE) levels were assessed prior to treatment and following one, two and three years of treatment. The median dose of ICS was reduced in the treatment group after two and three years of treatment compared with that of the control group. After three years of treatment, the discontinuation percentage of ICS in the treatment group was higher than that in the control group. The treatment group demonstrated significantly reduced daytime and night-time asthmatic symptom scores, increased PEF values and reduced serum IgE levels after two and three years of treatment compared with those in the control group (P<0.05). In conclusion, three-year SCIT treatment combined with ICS is an effective immunotherapy for children with allergic asthma and resulted in a reduction of the required ICS dose.
Exp Ther Med. 2014 Mar;7(3):630-634. Epub 2014 Jan 2
